BC
KPTI icon

Bridgefront Capital’s Karyopharm Therapeutics KPTI Stock Holding History

Bridgefront Capital’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,626
Closed -$157K – 352
2021
Q4 		$157K Buy
1,626
+230
+16% +$22.9K 0.15% 261
2021
Q3 		$122K Buy
+1,396
New +$145K 0.13% 265
2021
Q2 		– Sell
-2,492
Closed -$393K – 763
2021
Q1 		$393K Buy
2,492
+1,492
+149% +$314K 0.12% 334
2020
Q4 		$232K Buy
+1,000
New +$232K 0.08% 465

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ITP
Iron Triangle Partners Cos Cob, Connecticut $875M AUM 49.85% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Bridgefront Capital's KPTI Position: Q1 2022 in Review

Bridgefront Capital sold out of Karyopharm Therapeutics (KPTI) in Q1 2022, closing a stake of 1,626 shares — an estimated $157K sold.

Bridgefront Capital first reported a position in KPTI in Q4 2020 and held it in 4 quarters. The position peaked at $393K in Q1 2021. 139 funds tracked by Wall St. Rank hold KPTI as of Q1 2022.

  • Bridgefront Capital reported no remaining Karyopharm Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Bridgefront Capital sold 1,626 Karyopharm Therapeutics shares in Q1 2022, an estimated $157K.
  • Bridgefront Capital first reported a position in Karyopharm Therapeutics in Q4 2020 and held it in 4 quarters.
  • Bridgefront Capital's Karyopharm Therapeutics position peaked at $393K in Q1 2021.
  • 139 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2022.

Based on Bridgefront Capital's 13F filing for Q1 2022, filed 13 May 2022.